Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2017 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The question asks if a substantial part of the forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies, such that the company's own coming volume is a consequence of those parties' trajectories. Looking at the transcript, management discusses the company's backlog, market penetration, and product capabilities. They mention "record backlog" and "market penetration" as drivers. They talk about the opportunity in China, but that's more about market trends and content growth. They mention specific customers? They talk about "Ford Motor Company" in the context of pass car rotation, but that's a risk, not a growth trajectory. They mention "Grupo Antolin" acquisition, but that's an acquisition, not a counterparty's expansion. They talk about 48-volt opportunities with "six customers and 27 nameplates" - that's about their own awards, not the customers' own trajectories. They don't describe customers' own ramps or build-outs. They talk about "preproduction development with several luxury automakers" but that's not yet in production. They don't narrate counterparties' own expansion plans as the driver. The forward account is about their own backlog, market share, and product capabilities. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.